Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
An innovative machine learning model predicts the success of immune checkpoint inhibitors in cancer patients using routine blood tests and clinical data, outperforming traditional methods like tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback